Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares Outstanding
Ratios

Enanta Pharmaceuticals (ENTA) Leases (2019 - 2025)

Historic Leases for Enanta Pharmaceuticals (ENTA) over the last 7 years, with Q4 2025 value amounting to $37.0 million.

  • Enanta Pharmaceuticals' Leases fell 673.47% to $37.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $37.0 million, marking a year-over-year decrease of 673.47%. This contributed to the annual value of $37.5 million for FY2025, which is 764.67% down from last year.
  • According to the latest figures from Q4 2025, Enanta Pharmaceuticals' Leases is $37.0 million, which was down 673.47% from $37.5 million recorded in Q3 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Leases peaked at $41.2 million during Q2 2024, and registered a low of $4.7 million during Q3 2021.
  • For the 5-year period, Enanta Pharmaceuticals' Leases averaged around $26.1 million, with its median value being $23.8 million (2022).
  • Its Leases has fluctuated over the past 5 years, first tumbled by 3289.17% in 2021, then soared by 40042.45% in 2022.
  • Enanta Pharmaceuticals' Leases (Quarter) stood at $18.8 million in 2021, then increased by 24.99% to $23.5 million in 2022, then dropped by 9.33% to $21.3 million in 2023, then skyrocketed by 85.88% to $39.7 million in 2024, then fell by 6.73% to $37.0 million in 2025.
  • Its Leases was $37.0 million in Q4 2025, compared to $37.5 million in Q3 2025 and $38.2 million in Q2 2025.